Long-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experience

dc.contributor.authorTheerasuk Kawamatawongen_US
dc.contributor.authorOrapan Poachanukoonen_US
dc.contributor.authorChalermporn Boonsirien_US
dc.contributor.authorAtik Saengasapaviriyaen_US
dc.contributor.authorChanchai Sittipunten_US
dc.contributor.authorKittipong Maneechotesuwanen_US
dc.contributor.authorPintip Ngamchanyapornen_US
dc.contributor.authorKunchit Piyavechviratanaen_US
dc.contributor.authorPraparn Yongjaiyuten_US
dc.contributor.authorApichart Khanisapen_US
dc.contributor.authorSiwasak Juthongen_US
dc.contributor.authorWarangkana Rithiraken_US
dc.contributor.authorPrapaporn Pornsuriyasaken_US
dc.contributor.authorChaicharn Pothiraten_US
dc.contributor.authorWatchara Boonsawaten_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherFaculty of Medicine, Thammasat Universityen_US
dc.contributor.otherRoyal Thai Air Forceen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.contributor.otherPrince of Songkla Universityen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherThai Asthma Councilen_US
dc.description.abstractBACKGROUND: To evaluate long-term effectiveness of omalizumab in 'real-life' setting of Thai asthmatic patients. METHODS: We conducted multi-center, observational study in severe asthma patients who received omalizumab in Thailand. Outcomes were asthma exacerbation (hospitalization and ER visit), asthma control test (ACT), and daily ICS dose. Data were evaluated at baseline, 16 Week, and 52 Week. RESULTS: A total of 78 patients received omalizumab treatment (average duration 16.9 months with range 16 weeks-2 years). The mean annualized rate of exacerbations was reduced from baseline (3.79) at Week 16 (3.54) and Week 52 (1.16), (p<0.05), respectively. The mean hospitalization rate was reduced from 0.49 in previous year to 0.15 at Week 16 and 0.19 at Week 52. A reduction in ER visit rates was observed at Week 16 (0.15) and Week 52 (0.97) respectively from baseline (1.44) (p<0.05). The ACT score increased from 15.4 at baseline to 20.6 at Week 16 (p<0.001) and increased to 21.5 at Week 52 (p<0.001). The number of patients with controlled asthma (ACT≥20) increased from 16 of 51 at baseline to 32 of 45 at Week 16 and 25 of 32 at week 52, respectively. The median daily dose of ICS equivalent to fluticasone was reduced from baseline 680 mcg to 500 mcg at Week 52. In all, 22 patients discontinued omalizumab after 1 year. Six patients who discontinued omalizumab were restarted due to relapse of symptoms. CONCLUSIONS: These data confirms the effectiveness of one-year duration of omalizumab treatment in Thai severe asthmatic patients. Furthermore, 27% of patients who discontinued treatment required restarting due to relapse of symptoms.en_US
dc.identifier.citationAsian Pacific journal of allergy and immunology. Vol.36, No.4 (2018), 238-243en_US
dc.rightsMahidol Universityen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleLong-term effectiveness of omalizumab treatment in Thai severe asthmatic patients: A real-life experienceen_US